Centrum 7/6  banner

Suboxone (buprenorphine and naloxone) sublingual film

Dr. Reddy’s announces the re-launch of its buprenorphine and naloxone sublingual film

Dr. Reddy’s announces the re-launch of its buprenorphine and naloxone sublingual film

PRINCETON, N.J.— Dr. Reddy’s Laboratories announced this week the re-launch of its buprenorphine and naloxone sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent generic version of Suboxone (buprenorphine and naloxone) sublingual film, in the U.S. market. The re-launch comes on the heels of a favorable

Dr. Reddy’s Laboratories announces favorable outcome in patent litigation

Dr. Reddy’s Laboratories announces favorable outcome in patent litigation

HYDERABAD, India and PRINCETON, N.J. — Dr. Reddy’s Laboratories announced last week that the United States Court of Appeals for the Federal Circuit issued a decision in favor of Dr. Reddy’s Laboratories Inc., concluding that Indivior had not shown that it is likely to succeed on the merits of its infringement case on U.S. Patent

PP_1170x120_10-25-21